Corticalis AS was founded in 2001 by
Prof. Jan Eirik Ellingsen and Prof. Staale Petter Lyngstadaas.
The two founders still own approximately 75% of the company, the remainder is owned by key persons within the organization. The company is devoted to research and development of bone regenerative technologies and biomaterials. The company is performing early-stage, pre-clinical in vitro and animal studies and all of its inventions are within the field described above.
The company’s main assets next to its researchers are its patents and patent applications, described more in detail under research. Since its inception, the company has successfully developed and licensed out/sold several patent portfolios to major players within the dental implant industry.
The Company is focusing all its R & D on its three new technologies, a titanium based ceramic bone graft material (NuBone®), a synthetic peptide family (NuPep™) and a paste for peri-implantitis treatment (NuGel™). NuBone is CE registered medical device.